Diabetes Funding Talks Go Dark Behind NIH Doors
Published Date: 3/25/2025
Notice
Summary
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a private virtual meeting on May 1, 2025, to review grant applications. This meeting affects researchers seeking funding for diabetes, digestive, and kidney disease studies. No public access or money changes are involved, but the review helps decide who gets research support.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22871, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for eye disease, neuronal injury, infectious diseases, and related projects. No public access is allowed to protect private info and trade secrets, but these reviews help decide who gets research money.
2026-22550, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding two closed virtual meetings on November 30, 2026, to review important grant applications. These meetings affect researchers applying for funding in cardiovascular sciences and tobacco regulatory science. No public access is allowed to protect private info and trade secrets, and the reviews help decide who gets research money.
2026-22558, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for health-related projects, ensuring privacy for sensitive information. No direct money changes are announced, but these reviews help decide who gets research grants.
2026-22339, Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human
The National Institutes of Health plans to give AntaraCore Systems, Inc. an exclusive license to use new catheter technology that treats dangerous heart rhythm problems called ventricular arrhythmia. This means AntaraCore will have special rights to develop and sell this life-saving treatment. If you want to comment or apply for a license, you must do so by December 2, 2026.
2026-22196, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a public meeting on May 12, 2027, to discuss important council business and review grant applications. People interested can attend in person or online, but space is limited and some parts of the meeting will be private to protect sensitive information. This meeting affects researchers and organizations seeking funding and sets the stage for future diabetes and kidney disease research support.
2026-22111, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a virtual meeting on June 4, 2027, to share updates and review grant applications and staff performance. The first half is open to the public, while the second half is private to protect personal privacy. This meeting affects researchers and staff involved with NICHD grants and projects, with no direct cost changes announced.
Previous / Next Documents
Previous: 2025-04977, Self-Regulatory Organizations; The Nasdaq Stock Market LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To (i) Introduce a New Fee Credit Under Equity 7, Section 118(a)(1) (Fees for Execution and Routing of Orders) and Amend the Fee Schedule; (ii) Introduce New Fees and Credits Under Equity 7, Section 118(b), (iii) Amend Equity 7, Section 118(e) (Opening Cross) and Introduce a New Fee Credit; and (iv) Eliminate the Excess Order Fee Credits at Equity 7, Section 118(m) and Remove Related Language in Equity 7, Section 114(d)(1)
Nasdaq is shaking up its fee schedule to make trading fairer and more rewarding! They’re adding new fee credits for certain order types, tweaking fees for the opening cross, and saying goodbye to some old excess order fee credits. These changes kick in right away and could save or cost traders a bit depending on how they trade.
Next: 2025-04981, National Institute on Drug Abuse; Notice of Meeting
The National Institute on Drug Abuse is holding a virtual meeting on May 13, 2025, to review grant applications and discuss important drug research topics. This meeting affects researchers and organizations seeking funding, with some parts open to the public and others private to protect sensitive info. No direct money changes are announced, but grant decisions could impact future funding.